Opportunity Information: Apply for RFA HL 12 004

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "Maximizing the Scientific Value of the NHLBI Biologic Specimen Repository Scientific Opportunities (R21)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
  • This funding opportunity was created on Feb 3, 2011 and posted on Feb 3, 2011.
  • Applicants must submit their applications by Aug 17, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
  • Each selected applicant is eligible to receive up to $150,000.00 in funding.
  • Eligible applicants include: Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Special district governments Independent school districts State governments Small businesses County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Private institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
  • Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
Apply for RFA HL 12 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The Maximizing the Scientific Value of the NHLBI Biologic Specimen Repository Scientific Opportunities (R21) funding opportunity (RFA-HL-12-004) is a National Heart, Lung, and Blood Institute (NHLBI) initiative designed to help researchers quickly generate new knowledge from biospecimens that have already been collected and stored in the NHLBI Biologic Specimen Repository (often referred to as the Biorepository). The core idea is to encourage exploratory or early-stage projects that can extract additional scientific and clinical value from existing samples, rather than funding new large-scale specimen collection efforts. Because it uses the NIH Exploratory/Developmental (R21) mechanism, the program is geared toward focused, hypothesis-driven or discovery-oriented work that can produce proof-of-concept results, validate novel methods, or open up new lines of investigation in heart, lung, and blood-related science.

This opportunity targets research across the NHLBI mission space, including heart disease, lung diseases, and blood diseases and blood resources. The emphasis on “using existing biospecimens” means investigators are expected to leverage what is already housed in the NHLBI Biorepository, which may include samples collected through prior NHLBI-supported studies and clinical investigations. Projects are expected to be built around the unique value of these specimens, such as enabling studies that would be difficult or expensive to reproduce today, supporting analyses in well-characterized cohorts, or applying modern technologies to legacy collections to answer new questions. In practical terms, strong applications typically align a clearly defined scientific question with the availability and characteristics of repository specimens, and explain how the proposed analyses will generate meaningful insights into disease mechanisms, risk prediction, biomarkers, treatment response, or other high-impact areas relevant to NHLBI priorities.

From a funding and structure standpoint, the FOA is a discretionary grant program with no cost sharing or matching requirement. The total estimated funding associated with the announcement is listed as $5,000,000, indicating NHLBI planned to support multiple awards over the life of the announcement, depending on application quality and program priorities. The award ceiling is $150,000, which signals that projects should be tightly scoped and efficient, with a realistic plan for what can be accomplished within a modest budget typical of exploratory work. As an R21, it is meant to support early-stage investigation and generate data that can later underpin larger, more definitive studies (for example, follow-on R01-level research), particularly when preliminary data may still be limited but the scientific rationale and potential payoff are strong.

Eligibility is broad and includes many types of domestic organizations and governmental entities. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations other than small businesses, and small businesses. Governmental eligibility spans state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly highlights inclusion of a wide range of institutions and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, U.S. territories or possessions, and tribal entities (including tribal organizations and tribal governments in categories specified in the announcement). This broad eligibility reflects NHLBI’s interest in enabling diverse research teams and institutions to make productive use of shared national biospecimen resources.

Key administrative details place the announcement in a historical window: it was posted and created on February 3, 2011, with an original and final closing date of August 17, 2012, and an archive date of September 17, 2012. The activity categories linked to the program are consistent with NHLBI’s scope, specifically CFDA 93.838 (Lung Diseases Research) and 93.839 (Blood Diseases and Resources Research), reinforcing that projects may address a wide range of cardiopulmonary and hematologic conditions, as well as cross-cutting blood resource questions.

Overall, the program is best understood as an incentive to “mine” existing NHLBI-held biospecimens for new discoveries, especially using innovative assays, emerging analytic approaches, or new biological questions that were not feasible when the samples were originally collected. The intended outcome is a measurable increase in scientific yield from the Biorepository, turning stored specimens into new insights about heart, lung, and blood diseases and related resources while keeping costs and timelines lower than studies requiring new recruitment and specimen collection. For applicants needing help accessing the full announcement online, the NIH Office of Extramural Research webmaster contact is provided (FBOWebmaster@OD.NIH.GOV), and the FOA’s official posting is linked through the NIH grants guide page associated with RFA-HL-12-004.

Frequently Asked Questions (FAQs)

What is the purpose of the "Maximizing the Scientific Value of the NHLBI Biologic Specimen Repository Scientific Opportunities (R21)" funding opportunity?

This funding opportunity (RFA-HL-12-004) is an NHLBI initiative intended to help researchers quickly generate new knowledge from biospecimens that have already been collected and stored in the NHLBI Biologic Specimen Repository (the Biorepository). The program encourages projects that extract additional scientific and clinical value from existing samples rather than supporting new, large-scale specimen collection efforts.

Which NIH grant mechanism does this opportunity use?

The opportunity uses the NIH Exploratory/Developmental Research Grant Award (R21) mechanism, which is designed for exploratory or early-stage research. Projects are expected to be focused, efficient, and capable of producing proof-of-concept or method validation results that can support future, larger studies.

What kinds of research projects are a good fit for this R21?

The FOA is geared toward hypothesis-driven or discovery-oriented analyses that leverage existing Biorepository samples to generate new insights. Examples of the kinds of outcomes emphasized include proof-of-concept findings, validation of novel methods, or the opening of new lines of investigation across heart, lung, and blood-related science.

What is the central emphasis of this program?

The central emphasis is on using existing biospecimens housed in the NHLBI Biorepository. Applicants are expected to build their projects around the unique value of these stored specimens, including the ability to study well-characterized cohorts, revisit legacy collections with modern technologies, or answer questions that would be difficult or expensive to address by collecting new samples today.

Does this program support collecting new biospecimens?

The core idea described in the opportunity is to generate new knowledge from biospecimens that have already been collected and stored. The program is positioned as an alternative to funding new large-scale specimen collection efforts.

What research areas are covered under the NHLBI mission space for this FOA?

The opportunity targets research across the NHLBI mission space, including heart disease, lung diseases, and blood diseases and blood resources. The goal is to produce meaningful scientific and clinical insights relevant to NHLBI priorities.

What types of scientific questions or outputs does NHLBI expect from projects using these specimens?

Applications are expected to explain how proposed analyses will generate meaningful insights into areas such as disease mechanisms, risk prediction, biomarkers, treatment response, or other high-impact topics relevant to heart, lung, and blood science.

Why use the NHLBI Biologic Specimen Repository instead of starting a new collection?

Using existing repository specimens can make studies faster and more cost-effective, especially when the specimens come from prior NHLBI-supported studies and clinical investigations. This can enable research that would be difficult, time-consuming, or expensive to reproduce today.

How much funding is available per award under this FOA?

The award ceiling listed for this opportunity is $150,000, which indicates projects should be tightly scoped and achievable within a modest exploratory budget.

What is the estimated total funding associated with this announcement?

The total estimated funding associated with the announcement is $5,000,000, reflecting NHLBI’s plan to support multiple awards over the life of the announcement based on application quality and program priorities.

Is cost sharing or matching required?

No. The FOA is described as a discretionary grant program with no cost sharing or matching requirement.

What types of organizations are eligible to apply?

Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations other than small businesses, and small businesses.

Are government entities eligible to apply?

Yes. Eligible governmental applicants include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.

Does the FOA encourage applications from specific institution types or communities?

Yes. The announcement explicitly highlights inclusion of a wide range of institutions and communities, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, U.S. territories or possessions, and tribal entities (including certain tribal organizations and tribal governments as specified in the announcement).

When was this funding opportunity posted and when did it close?

The announcement was posted/created on February 3, 2011. The original and final closing date was August 17, 2012. The archive date was September 17, 2012.

Which CFDA program areas are associated with this opportunity?

The activity categories linked to the program include CFDA 93.838 (Lung Diseases Research) and CFDA 93.839 (Blood Diseases and Resources Research), indicating that supported projects may align with lung diseases research as well as blood diseases and blood resources research.

What does "maximizing scientific value" mean in the context of this FOA?

In this context, it refers to increasing the scientific yield from stored specimens by applying innovative assays, emerging analytic approaches, or new biological questions that were not feasible at the time the samples were collected. The aim is to turn stored specimens into new insights about heart, lung, and blood diseases and related resources.

What is the intended role of this R21 in a larger research trajectory?

The R21 is positioned to support early-stage investigation and generate data that can underpin larger, more definitive studies later (for example, follow-on R01-level research), particularly when preliminary data may still be limited but the scientific rationale and potential payoff are strong.

Where can someone get help accessing the full official announcement?

The NIH Office of Extramural Research webmaster contact is provided as FBOWebmaster@OD.NIH.GOV, and the FOA’s official posting is linked through the NIH grants guide page associated with RFA-HL-12-004.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Independence Visitor Center Operation, Use and Maintenance

Previous opportunity: FY 2011 SaDIP Grant Opportunity Announcement

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA HL 12 004

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA HL 12 004) also looked into and applied for these:

Funding Opportunity
Childrens Health Insurance Program Reauthorization Act (CHIPRA) Outreach and Enrollment Grants Cycle II Apply for CMS 1Z0 11 001

Funding Number: CMS 1Z0 11 001
Agency: Centers for Medicare Medicaid Services
Category: Health
Funding Amount: $2,500,000
Impact Evaluation of Combination HIV Prevention Interventions in PEPFAR Countries Apply for RFA GH 11 006

Funding Number: RFA GH 11 006
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
NIMHD Comprehensive Centers of Excellence (P60) Apply for RFA MD 11 003

Funding Number: RFA MD 11 003
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NIMHD Exploratory Centers of Excellence (P20) Apply for RFA MD 11 002

Funding Number: RFA MD 11 002
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
HIV/AIDS and TB (HIV/TB) Program Component Apply for USAID SENEGAL RFA 685 11 A 11

Funding Number: USAID SENEGAL RFA 685 11 A 11
Agency: Senegal USAID Dakar
Category: Health
Funding Amount: $22,000,000
Health System Strenghtening (HSS) Program Component Apply for USAID SENEGAL RFA 685 11 A 12

Funding Number: USAID SENEGAL RFA 685 11 A 12
Agency: Senegal USAID Dakar
Category: Health
Funding Amount: $20,000,000
Health Services Improvement (HSI) Program Component Apply for USAID SENEGAL RFA 685 11 A 13

Funding Number: USAID SENEGAL RFA 685 11 A 13
Agency: Senegal USAID Dakar
Category: Health
Funding Amount: $32,000,000
Strengthening the Human Resource Capacity in the Republic of Zambia to Provide Quality Care for HIV/AIDS through the Development of a Cadre of Local Experts in HIV/AIDS under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1118

Funding Number: CDC RFA GH11 1118
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
The National Healthy Tomorrows Technical Assistance Resource Center Apply for HRSA 11 125

Funding Number: HRSA 11 125
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Community Health (CH) Program Component Apply for USAID SENEGAL RFA 685 11 A 14

Funding Number: USAID SENEGAL RFA 685 11 A 14
Agency: Senegal USAID Dakar
Category: Health
Funding Amount: $40,000,000
Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Regional Health Bureaus of Oromiya and Harari Regional States and Dire Dawa City Administration of the Federal Democratic Republic of Ethiopia under PEPFAR Apply for CDC RFA GH11 1106

Funding Number: CDC RFA GH11 1106
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Building the Capacity of Provincial Medical Offices (PHOs) in the Republic of Zambia to Provide Comprehensive and Sustainable HIV/AIDS Prevention, Care, Support, and Treatment Services in Eastern, Lusaka, and Western Provinces of the Republic of Zamb Apply for CDC RFA GH11 1122

Funding Number: CDC RFA GH11 1122
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Engaging Local Indigenous Partners in the Implementation and Expansion of High Quality HIV Care, Prevention and Treatment Activities in Faith Based, Affiliated Sites in the Republic of Kenya under the President s Emergency Plan for AIDS Relief (PEPFA Apply for CDC RFA GH11 1103

Funding Number: CDC RFA GH11 1103
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention Services in Faith Based Health Facilities and Procurement and Logistics Management of Health Related Commodities for HHS/CDC Funded HIV/AIDS Programs in the Republic of Uganda under P Apply for CDC RFA GH11 1113

Funding Number: CDC RFA GH11 1113
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Child and Adolescent Injury and Violence Prevention Resource Centers Cooperative Agreement Apply for HRSA 11 103

Funding Number: HRSA 11 103
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Implementation of Programs for the Prevention, Care and Treatment of HIV/AIDS in the Republic of Cote d Ivoire under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1116

Funding Number: CDC RFA GH11 1116
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS) Apply for USAID NIGERIA HIV 11 004 RFA

Funding Number: USAID NIGERIA HIV 11 004 RFA
Agency: Nigeria USAID Abuja
Category: Health
Funding Amount: $225,000,000
Engaging Local Indigenous Organizations in the Implementation and Provision of Comprehensive HIV Care, Treatment, and Prevention Services in Six States of the Federal Republic of Nigeria under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1124

Funding Number: CDC RFA GH11 1124
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Supporting Indigenous Organizations to Implement and Expand Comprehensive HIV/AIDS Prevention, Care and Treatment in the Republic of Mozambique under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1130

Funding Number: CDC RFA GH11 1130
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Improving Care And Treatment For TB/HIV Co Infected Children Through The Establishment Of Comprehensive Pediatric TB/HIV Activities In The United Republic Of Tanzania Under The President s Emergency Plan For AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1107

Funding Number: CDC RFA GH11 1107
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 004", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.